{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:27:44Z","timestamp":1789183664065,"version":"build-2803163510"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Clinical trial data for dupilumab, a monoclonal antibody against the interleukin\u20104 receptor (IL\u20104R\u03b1), have shown that it is safe and effective for the treatment of moderate to severe atopic dermatitis in patients whose disease is resistant to other therapies. However, little real\u2010world experience with dupilumab use has been reported thus far. The aim of this retrospective study was to assess overall outcomes in adult patients with atopic dermatitis (AD) treated with dupilumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review of electronic medical records was conducted for patients treated with dupilumab in the Department of Dermatology at the University of California, Irvine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We analyzed the medical records of 77 AD patients who received dupilumab according to standard dosing and had at least one documented follow\u2010up visit. In 66 patients (86%), dupilumab improved clinical disease severity, with 23 patients (30%) experiencing complete clearance on dupilumab. Dupilumab was generally well\u2010tolerated and caused no serious adverse events. The most common side effects included dry eyes, conjunctivitis, and keratitis. The most common reason for discontinuation of treatment was lack of substantial clinical improvement or progression of disease severity, followed by ophthalmologic side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, dupilumab was well\u2010tolerated and resulted in clinical improvement in our patient population. These results provide additional important information on the safety and utility of dupilumab treatment for moderate to severe atopic dermatitis in the real\u2010world clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.14573","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T06:29:16Z","timestamp":1562653756000},"page":"253-256","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Real\u2010world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records"],"prefix":"10.1111","volume":"59","author":[{"given":"Candice","family":"Wang","sequence":"first","affiliation":[{"name":"Western University of Health Sciences Pomona California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina N.","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krupa G.","family":"Patel","sequence":"additional","affiliation":[{"name":"Oakland University William Beaumont School of Medicine Rochester Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand K.","family":"Ganesan","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei A.","family":"Grando","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01027.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.251"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.017"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.00191.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.012"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0768-3"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15118"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.053"},{"key":"e_1_2_5_14_1","unstructured":"US FDA.Dupixent\u00ae (dupilumab) injection for subcutaneous use: US prescribing information.2017.https:\/\/www.fda.gov. Accessed 21 Dec 2018."}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14573","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.14573","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T02:11:56Z","timestamp":1694139116000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.14573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/ijd.14573"],"URL":"https:\/\/doi.org\/10.1111\/ijd.14573","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"2019-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}